Edasalonexent, an oral NF-κB inhibitor, in development for treatment of Duchenne muscular dystrophy: the phase 3 POLARIS study design

被引：0
|
作者：
Finkel, R. [1 ]
McDonald, C. [2 ]
Sweeney, H. [3 ]
Mancini, M. [4 ]
MacDougall, J. [4 ]
Donovan, J. [4 ]
机构：
[1] Univ Cent Florida, Orlando, FL 32816 USA
[2] Univ Calif Davis, Sacramento, CA USA
[3] Univ Florida, Gainesville, FL USA
[4] Catabasis Pharmaceut Inc, Cambridge, MA USA
来源：
NEUROMUSCULAR DISORDERS | 2018年 / 28卷
关键词：
D O I：
10.1016/j.nmd.2018.06.145
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.117
引用
收藏
页码：S64 / S64
页数：1
相关论文
共 50 条
  • [1] Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy
    Finanger, Erika
    Vandenborne, Krista
    Finkel, Richard S.
    Sweeney, H. Lee
    Tennekoon, Gihan
    Yum, Sabrina
    Mancini, Maria
    Bista, Pradeep
    Nichols, Andrew
    Liu, Hanlan
    Fretzen, Angelika
    Donovan, Joanne M.
    JOURNAL OF NEUROMUSCULAR DISEASES, 2019, 6 (01) : 43 - 54
  • [2] A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy
    Vita, Gian Luca
    Sframeli, Maria
    Licata, Norma
    Bitto, Alessandra
    Romeo, Sara
    Frisone, Francesca
    Ciranni, Annamaria
    Pallio, Giovanni
    Mannino, Federica
    Aguennouz, M'Hammed
    Rodolico, Carmelo
    Squadrito, Francesco
    Toscano, Antonio
    Messina, Sonia
    Vita, Giuseppe
    BRAIN SCIENCES, 2021, 11 (01) : 1 - 12
  • [3] MoveDMD: phase 2 trial of edasalonexent, an NF-κB inhibitor, in 4 to 7-year old patients with Duchenne muscular dystrophy
    Finkel, R.
    Vandenborne, K.
    Sweeney, H.
    Finanger, E.
    Tennekoon, G.
    Shieh, P.
    Willcocks, R.
    Forbes, S.
    Triplett, W.
    Yum, S.
    Mancini, M.
    Friedman, M.
    Fretzen, A.
    Donovan, J.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S215 - S215
  • [4] CAT-1004, an oral agent targeting NF-κB in development for treatment of Duchenne muscular dystrophy: Phase 1/2 study design
    Donovan, J.
    Sweeney, H.
    Vandenborne, K.
    Russman, B.
    Jirousek, M.
    Finkel, R.
    NEUROMUSCULAR DISORDERS, 2015, 25 : S262 - S262
  • [5] Treatment of young boys with Duchenne muscular dystrophy with the NF-κB inhibitor edasalonexent showed a slowing of disease progression as assessed by MRI and functional measures
    Finkel, R.
    Vandenborne, K.
    Sweeney, H.
    Finanger, E.
    Tennekoon, G.
    Shieh, P.
    Willcocks, R.
    Walter, G.
    Rooney, W.
    Forbes, S.
    Triplett, W.
    Yum, S.
    Mancini, M.
    MacDougall, J.
    Fretzen, A.
    Bista, P.
    Nichols, A.
    Donovan, J.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S208 - S208
  • [6] Treatment of Young Boys with Duchenne Muscular Dystrophy with the NF-κB Inhibitor Edasalonexent Showed a Slowing of Disease Progression as Assessed by MRI and Functional Measures
    Finkel, R.
    Vandenborne, K.
    Sweeney, H.
    Finanger, E.
    Tennekoon, G.
    Shieh, P.
    Willcocks, R.
    Walter, G.
    Rooney, W.
    Forbes, S.
    Triplett, W.
    Yum, S.
    Mancini, M.
    MacDougall, J.
    Donovan, J.
    ANNALS OF NEUROLOGY, 2019, 86 : S29 - S29
  • [7] A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects
    Donovan, Joanne M.
    Zimmer, Michael
    Offman, Elliot
    Grant, Toni
    Jirousek, Michael
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (05): : 627 - 639
  • [8] MoveDMD®: Positive Effects of Edasalonexent, an NF-κB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy in Phase 2 Study with an Open-Label Extension
    Finkel, Richard
    Vandenborne, Krista H. E.
    Sweeney, H. Lee
    Finanger, Erika
    Tennekoon, Gihan
    Shieh, Perry
    Willcocks, Rebecca J.
    Forbes, Sean C.
    Triplett, William
    Yum, Sabrina
    Mancini, Maria
    Fretzen, Angelika
    Donovan, Joanne
    NEUROLOGY, 2018, 90
  • [9] Edasalonexent, an NF-κB Inhibitor, slows disease progression over more than a year compared to control period in 4 to 7 year old patients with Duchenne muscular dystrophy
    Richard, F.
    Vandenborne, K.
    Sweeney, H.
    Finanger, E.
    Tennekoon, G.
    Shieh, P.
    Willcocks, R.
    Walter, G.
    Rooney, W.
    Forbes, S.
    Triplett, W.
    Yum, S.
    Mancini, M.
    MacDougall, J.
    Fretzen, A.
    Bista, P.
    Nichols, A.
    Donovan, J.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S64 - S64
  • [10] Disease-modifying effects of edasalonexent, an NF-KB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial
    Finkel, Richard S.
    Finanger, Erika
    Vandenborne, Krista
    Sweeney, H. Lee
    Tennekoon, Gihan
    Shieh, Perry B.
    Willcocks, Rebecca
    Walter, Glenn
    Rooney, William D.
    Forbes, Sean C.
    Triplett, William T.
    Yum, Sabrina W.
    Mancini, Maria
    MacDougall, James
    Fretzen, Angelika
    Bista, Pradeep
    Nichols, Andrew
    Donovan, Joanne M.
    NEUROMUSCULAR DISORDERS, 2021, 31 (05) : 385 - 396
12345